Condition: Acute Lymphoblastic Leukemia · Lymphoma · Multiple Myeloma · Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.
This description comes directly from the study's public registry record.
Weiwei w Tian, MD · 008613485304136 · tianweiwei@yeah.net
Na Kuang, MD · 008618630160116 · kuangna@senlangbio.com
Always discuss trial participation with your own doctor first.
| Shanxi Bethune Hospital | Taiyuan, Shanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05618041